Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation versus observation in elderly DLBCL in CR after R-CHOP
2011-004916-51Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jun 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Sequential Zevalin consolidation with Observation (2 arms). Primary endpoint: Overall survival. Started Jun 2012; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-004916-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004916-51.